Search｜Photos & Images & Videos｜KYODO NEWS IMAGES INC

Illustrations Doliprane Sanofi - Lisieux

The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM

E

Illustrations Doliprane Sanofi - Lisieux

The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM

E

Illustrations Doliprane Sanofi - Lisieux

The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM

E

Illustrations Doliprane Sanofi - Lisieux

The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM

E

Illustrations Doliprane Sanofi - Lisieux

The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM

E

Illustrations Doliprane Sanofi - Lisieux

The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM

E

Illustrations Doliprane Sanofi - Lisieux

The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM

E

Illustrations Doliprane Sanofi - Lisieux

The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM

E

Illustrations Doliprane Sanofi - Lisieux

The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM

E

Illustrations Doliprane Sanofi - Lisieux

The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM

E

Illustrations Doliprane Sanofi - Lisieux

The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM

E

Illustrations Doliprane Sanofi - Lisieux

The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM

E

Illustrations Doliprane Sanofi - Lisieux

The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM

E

Illustrations Doliprane Sanofi - Lisieux

The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM

E

Illustrations Doliprane Sanofi - Lisieux

The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM

E

Illustrations Doliprane Sanofi - Lisieux

The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM

E

Illustrations Doliprane Sanofi - Lisieux

The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM

E

Illustrations Doliprane Sanofi - Lisieux

The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM

E

Illustrations Doliprane Sanofi - Lisieux

The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM

E

Illustrations Doliprane Sanofi - Lisieux

The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM

E

Illustrations Doliprane Sanofi - Lisieux

The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM

E

Illustrations Doliprane Sanofi - Lisieux

The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM

E

Illustrations Doliprane Sanofi - Lisieux

The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM

E

Illustrations Doliprane Sanofi - Lisieux

The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM

E

Illustrations Doliprane Sanofi - Lisieux

The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM

E

Illustrations Doliprane Sanofi - Lisieux

The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM

E

Illustrations Doliprane Sanofi - Lisieux

The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM

E

Illustrations Doliprane Sanofi - Lisieux

The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM

E

Illustrations Doliprane Sanofi - Lisieux

The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM

E

Illustrations Doliprane Sanofi - Lisieux

The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM

E

Illustrations Doliprane Sanofi - Lisieux

The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM

E

Illustrations Doliprane Sanofi - Lisieux

The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM

E

Illustrations Doliprane Sanofi - Lisieux

The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM

E

Illustrations Doliprane Sanofi - Lisieux

The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM

E

Illustrations Doliprane Sanofi - Lisieux

The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM

E

Illustrations Doliprane Sanofi - Lisieux

The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM

E

Illustrations Doliprane Sanofi - Lisieux

The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM

E

Illustrations Doliprane Sanofi - Lisieux

The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM

E

Illustrations Doliprane Sanofi - Lisieux

The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM

E

Illustrations Doliprane Sanofi - Lisieux

The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM

E

Illustrations Doliprane Sanofi - Lisieux

The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM

E

Illustrations Doliprane Sanofi - Lisieux

The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM

E

Illustrations Doliprane Sanofi - Lisieux

The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM

E

Illustrations Doliprane Sanofi - Lisieux

The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM

E

Illustrations Doliprane Sanofi - Lisieux

The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM

E

Illustrations Doliprane Sanofi - Lisieux

The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM

E

Illustrations Doliprane Sanofi - Lisieux

The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM

E

Illustrations Doliprane Sanofi - Lisieux

The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM

E

70359 04

Thierry Desmarest, Chief Executive Officer of Total, attends Sanofi-Synthelabo general shareholders' meeting in Paris, France on June 23, 2004. Photo by Lucas Schifres/ABACA